A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin® in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

NCT01179776 Phase 1/Phase 2 COMPLETED

Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of Ilomedin and to low dose of standard treatment for another 24 hours.

Details

Lead sponsor	Thrombologic ApS
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	16
Start date	2010-09
Completion	2011-06

Conditions

• Myocardial Infarct

Interventions

• Ilomedin
• Placebo
• Ilomedin
• Ilomedin and standard low dose treatment

Primary outcomes

• Bleeding complications as evaluated by TIMI and GUSTO criteria — Feb 2011
  Increased bleeding complications will be evaluated between the active and placebo groups.

Countries

Denmark